Biogen Idec (NASDAQ:BIIB) is absolutely humiliating Wall Street analysts with truly impressive second quarter results.
The big biotech saw monumental gains as revenue soared 40% and adjusted earnings grew 52% year over year. Importantly, this isn't a one time bump, the company's new earnings guidance is a full 14% higher for the year. The star of the show is oral mutiple sclerosis drug Tecfidera which saw sales more than triple to $700 million.
In this video Motley Fool health care analysts David Williamson and Michael Douglass, discuss what powered Biogen's amazing quarter, give key takeaways, and explain why they are so excited about the stock.